(Boursier.com) — OSE Immuno SA, announces that three abstracts have been accepted for poster presentation at the 37th annual meeting of the SITC (Society for Immunotherapy of Cancer) to be held in Boston in person and virtually from November 8 to 12.
These posters will present the latest preclinical data from the innovative BiCKI and Myeloid research platforms, and in particular on the BiCKI-IL-7 (bifunctional targeting PD-1 and IL-7) and CLEC-1 (new myeloid immune checkpoint) programs. ). The Company had also been invited to make an oral presentation on its CLEC-1 program at the Macrophage-directed Therapies Summit in Boston in October 2022.
INFORMATION ON PRESENTATIONS AT SITC 2022
– Title: “IL7R TME expression correlates with immunotherapy response and is associated with T-cell
stemness with decreased apoptosis” (poster 826)
Category: Combination Immunotherapies
Date of presentation: November 11, 2022
– Title: “Anti-PD-1/IL-7v bispecific antibody promotes TCF1+ stem like T cells expansion and longlasting in vivo efficacy”
Category: Novel Single-Agent Immunotherapies
Date of presentation: November 11, 2022
CLEC-1 program
– Title: “Blockade of the myeloid CLEC-1 checkpoint enhances antitumor responses and tumor antigen
cross-presentation” (abstract 484)
Category: Checkpoint Blockade Therapy
Date of presentation: November 11, 2022
ORAL PRESENTATION AT MACROPHAGE-DIRECTED THERAPIES SUMMIT 2022
– Title: “The C-type Lectin CLEC-1 is a Sensor of Cell Death Limiting Myeloid Cell Functions and AntiTumor Immunity”
Date of presentation: October 4, 2022.
©2022 Boursier.com